Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | OTC | P00480 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 3/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242961 | 0.86 | HDAC1 (0.58) | POLBKMT2ATDP1NAAAHDAC3 | |
| SCHEMBL24130547 | 0.86 | HDAC1 (0.58) | POLBKMT2ATDP1NAAAHDAC3 | |
| SCHEMBL345305 | 0.86 | HDAC1 (0.58) | POLBKMT2ATDP1NAAAHDAC3 | |
| SCHEMBL11583619 | 0.85 | HDAC1 (0.53) | KMT2ATDP1NAAAHDAC3HDAC4 | |
| SCHEMBL29516940 | 0.83 | DPP8 (0.47) | TDP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2237833 | 0.81 | EPHX2 (0.57) | POLBKMT2ATDP1OTCNAAA | |
| SCHEMBL2237828 | 0.81 | EPHX2 (0.57) | POLBKMT2ATDP1OTCNAAA | |
| SCHEMBL8192638 | 0.81 | HDAC3 (0.52) | POLBKMT2ATDP1NAAAHDAC3 | |
| SCHEMBL1009383 | 0.80 | OTC (0.49) | POLBKMT2ATDP1OTCNAAA | |
| SCHEMBL2464340 | 0.80 | OTC (0.49) | POLBKMT2ATDP1OTCNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253345-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2019-04-09 | — | — | US | disclosed |
| EP-2898085-B1 | CELL LINES | MEDIMMUNE LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20170306381-A1 | CELL LINES | ALLOZYNE, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170306380-A1 | AMINO ACID DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-9732367-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9670521-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-20160024522-A1 | NOVEL NUCLEIC ACID MOLECULES | ALLOZYNE, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150259721-A1 | CELL LINES | ALLOZYNE, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150251994-A1 | AMINO ACID DERIVATIVES | ALLOZYNE, INC. | 2015-09-10 | — | — | US | disclosed |
| WO-2014044872-A1 | CELL LINES | ALLOZYNE, INC (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014044873-A1 | AMINO ACID DERIVATIVES | ALLOZYNE, INC (US) | 2014-03-27 | — | — | WO | disclosed |
| US-6676928-B2 | AS CONTRAST MEDIA FOR THE VISUALIZATION OF MALIGNANT TUMORS, LYMPH NODES AND NECROTIC TISSUE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259721-A1 | CELL LINES | AARS1, LARS1, IARS1 | POLB 1815/4885KMT2A 1119/4885TDP1 863/4885 |
| US-10253345-B2 | Cell lines | AARS1, LARS1, IARS1 | POLB 1815/4885KMT2A 1119/4885TDP1 863/4885 |
| US-20150251994-A1 | AMINO ACID DERIVATIVES | BCAT2, DNPEP, BCAT1 | POLB 4346/4885KMT2A 3685/4885TDP1 4070/4885 |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | FFAR1, FGB, FCGRT | POLB 753/4885KMT2A 4174/4885TDP1 3802/4885 |
| US-20170306381-A1 | CELL LINES | AARS1, LARS1, IARS1 | POLB 1815/4885KMT2A 1119/4885TDP1 863/4885 |
| US-20170306380-A1 | AMINO ACID DERIVATIVES | BCAT2, DNPEP, BCAT1 | POLB 4346/4885KMT2A 3685/4885TDP1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.